# ADOPT-lung (NCT06284317)

> A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: stage IIB-IIIB (N2) resectable NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06284317
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ETOP IBCSG Partners Foundation
- Conditions: Non Small Cell Lung Cancer
- Interventions: Adjuvant durvalumab
- Enrollment: 290
- Primary outcome: Disease-free survival (DFS)

## Some of the questions raised in the 16 indexed sources

_Automated from all 16 indexed sources (Dec 2024 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adjuvant durvalumab adds benefit after neoadjuvant chemotherapy plus durvalumab, or neoadjuvant-only treatment suffices
- Whether patients without a pathologic complete response gain from adjuvant durvalumab while those with one do not
- Whether PD-L1-negative or higher-stage disease identifies who needs the adjuvant durvalumab phase
- Whether a further year of adjuvant durvalumab after surgery is needed or amounts to overtreatment

## Indexed commentary on ADOPT-lung so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 4 podcast episodes
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=adopt-lung-nct06284317

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06284317", "email": "<work email>"}; the inbox owner confirms by the emailed link.